Polaryx Therapeutics, Inc. (NASDAQ:PLYX) ("Polaryx" or the "Company"), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (LSDs), today announces the activation of the first clinical trial site for SOTERIA, its Phase 2 basket trial evaluating the Company's lead investigational drug candidate, PLX-200, across four rare pediatric LSDs.  Boys Town National Research Hospital in Boys Town, Nebraska, where the study is being led by Isabella Herman, M.D., Ph.D., a pediatric neurologist and neurogeneticist, is now positioned to begin protocol-directed screening of eligible pediatric participants for SOTERIA. Boys Town is an affiliate center in the Batten Disease Support, Research, and Advocacy (BDSRA) Foundation's Batten Disease Clinical Center of Excellence Program and provides multidisciplinary care for children with rare neurogenetic disorders.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.